

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Alenfalk, Dahlström, Hunegnaw, Karlsson, Lemurell, Lindqvist, Skjäret, and Starke**

Title: Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity

Serial No.: **10/596,731**

Group Art Unit: **1624**

Filed: **November 16, 2006**

Examiner: **Mark L. Berch**

Confirmation No.: **9947**

Filed by EFS Web on: **8 March 2010**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE UNDER 37 C.F.R. §1.111

In response to the Office Action dated September 17, 2009 in regard to the above-identified patent application, Applicants respectfully request that the application be amended as follows. The period for responding to the Office Action has been extended, by enclosure of a petition and appropriate fee, to and through March 17, 2010.

Amendment if the specification begins at page 2.

Amendment of the claims begins at page 3.

Remarks begin at page 13.